A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy
Rajiv Raman,Kim Ramasamy,Utkarsh Shah
DOI: https://doi.org/10.2147/OPTH.S374165
2022-09-09
Clinical Ophthalmology
Abstract:Rajiv Raman, 1 Kim Ramasamy, 2 Utkarsh Shah 3 1 Shri Bhagwan Mahavir Vitreoretinal Services, Chennai, Tamil Nadu, India; 2 Aravind Eye Hospital, Madurai, Tamil Nadu, India; 3 Novartis Healthcare Private Limited, Mumbai, India Correspondence: Rajiv Raman, Shri Bhagwan Mahavir Vitreoretinal Services, Chennai, Tamil Nadu, India, Tel +91-9444288708, Email Diabetic retinopathy (DR) is considered one of the leading causes of vision loss globally. It principally causes upregulation of pro-angiogenic, proinflammatory, and vascular permeability factors such as vascular endothelial growth factor (VEGF), leading to neovascularisation. The advanced stage of DR or proliferative diabetic retinopathy (PDR) is of more concern, as it leads to vitreous haemorrhage and traction retinal detachment. Various risk factors associated with PDR include hyperglycemia, hypertension, neuropathy, dyslipidemia, anaemia, nephropathy, and retinal complications of drugs used for diabetes. Current management approaches for PDR have been stratified and involve pan-retinal photocoagulation, vitrectomy, and anti-VEGF agents. Given the emerging role of anti-VEGF agents as a favourable adjunct or alternative therapy, they have a critical role in the management of PDR. The review emphasises current management approaches for PDR focusing on anti-VEGF therapy. The review also highlights the risk/benefit evaluation of the various approaches employed for PDR management in various clinical scenarios. Keywords: neovascularisation, diabetic retinopathy, pan-retinal photocoagulation, vitrectomy, anti-VEGF, PDR in India Diabetes mellitus (DM) is one of the most common noncommunicable diseases in the world. 1 According to International Diabetes Federation Atlas 2021, it was estimated that approximately 537 million individuals in the world had diabetes (types 1 and 2), aged between 20 and 79 years representing 10.5% of the world population. India ranks second in terms of disease burden globally with around 74.2 million individuals having diabetes. 2 The national survey conducted in India establishes the prevalence of DM to be 11.2%. 3 It was established that diabetic retinopathy (DR) is one of the major diabetes-related complication having vision loss as a global concern, leading to substantial financial implications. 4 The global prevalence of DR was observed to be ranging between 22% and 35% in patients with diabetes as reported in different studies. 5–7 In 2020, the individuals affected with DR is estimated to be 103.12 million which is projected to increase to 160.50 million by 2045. 6 However, a disproportionate representation of DR is observed across geography where maximum prevalence is observed in Middle East and North Africa and the Western Pacific. 6 Additionally, no significant inter-gender difference was observed in the DR prevalence (females: 25.93%; males: 28.95%). 7 Sight-threatening DR or vision-threatening DR is defined as "presence of severe non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR) and/or macular oedema in at least one eye". 8 The incidence of sight-threatening DR is more in type 1 when compared with type 2 DM. 9 Advanced DR or PDR represents angiogenic response of the retina to extensive ischaemia from capillary closure. 10 The characteristics of PDR include retinal neovascularisation (NV), serum leakage, haemorrhage, and fibrovascular proliferation in the vitreous retinal interface. The characteristic clinical feature of PDR is growth of new vessels arising at the interface of perfused or nonperfused retina, viz. new vessels on the disc (NVD) or new vessels elsewhere (NVE). All these characteristics ultimately lead to vitreous haemorrhage (VH) and traction retinal detachment (TRD). 11 In some instances, new vessels on the iris (NVI) and iridocorneal angle (NVA) also develop owing to advanced posterior segment ischaemic changes. 12 Experimentally, it has been observed that elevated levels of vascular endothelial growth factor (VEGF) induce NV in mouse models and also that large amounts of miR-410 efficiently downregulates vascular endothelial growth factor expression, suppressing retinal NV. 13 Additionally, inhibition of intraocular VEGF was noted to prevent NVI in nonhuman primates. 14 It has also been reported that elevated levels of VEGF are found in the vitreous humour of patients with PDR. 15 Elevated levels of angiogenic factors are associated with endothelial cell proliferation and migration and disruption of tight junctions, which lead to new vessel formation and increased vascular permeability. Molecular studies have shown that VEGF-A encourages the process o -Abstract Truncated-